Mineralys Therapeutics, Inc. (MLYS) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Mineralys Therapeutics, Inc.
Address
150 N. Radnor Chester Rd.
Radnor, PA 19087
United States of America (the)
Phone
888-378-6240
Website
Sector
Healthcare
Industry
Biotechnology
Employees
76
First IPO Date
February 10, 2023
Key Executives
| Name | Title | Pay | Year Born |
| Jon Congleton | President, Chief Executive Officer & Director | 1.11M | 1963 |
| Brian Taylor Slingsby | Founder & Executive Director | 78,000 | 1977 |
| Adam Scott Levy | Chief Financial Officer & Secretary | 880,190 | 1978 |
| David Rodman | Chief Medical Officer | 881,798 | 1955 |
| Danielle Mahoney | Senior Vice President of Quality Assurance | 0 | N/A |
| Tiffany Ellen Burt | Senior Vice President of Medical Affairs | 0 | N/A |
| Eric J. Warren | Chief Commercial Officer | 0 | 1972 |
| Jeffrey A. Munsie | Chief Legal Officer | 0 | 1977 |
| Robert McKean | Senior Vice President of CMC | 0 | N/A |
| Jessica Ibbitson | Executive Vice President of Operations | 0 | N/A |
Description
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
